Really does Subsidiary Medicine Boost Danger Of Death for Cancer Tumors Clients?

Really does Subsidiary Medicine Boost Danger Of Death for Cancer Tumors Clients?

This information is part of the 2018 NMJ Oncology Special problem. Grab the full problem here.

Resource

Johnson SB, Park HS, Gross CP, Yu JB. Subservient medication, refusal of main-stream malignant tumors treatments, and success among people with treatable cancers. JAMA Oncol. 2018;4(10):1375-1381.

Concept

A retrospective observational review of information obtained from the National Cancer Database (NCDB)

Members

The first cohort provided 1,901,815 customers who were identified as having non-metastatic breasts, prostate, lung, or colorectal cancer tumors between 2004 and 2013. Continue reading “Really does Subsidiary Medicine Boost Danger Of Death for Cancer Tumors Clients?”